eFFECTOR Therapeutics, Inc.

OTCPK:EFTR Stock Report

Market Cap: US$940.0

eFFECTOR Therapeutics Past Earnings Performance

Past criteria checks 0/6

eFFECTOR Therapeutics's earnings have been declining at an average annual rate of -43.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 76.6% per year.

Key information

-43.2%

Earnings growth rate

80.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-76.6%
Return on equity-4,187.5%
Net Marginn/a
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

Revenue & Expenses Breakdown

How eFFECTOR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:EFTR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 240-35110
31 Dec 230-36110
30 Sep 231-36110
30 Jun 232-37120
31 Mar 234-36120
31 Dec 224-23130
30 Sep 2236160
30 Jun 22324170
31 Mar 22125160
31 Dec 21116130
30 Sep 211-480
30 Jun 211-2050
31 Mar 2116-750
31 Dec 2042040

Quality Earnings: EFTR is currently unprofitable.

Growing Profit Margin: EFTR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EFTR is unprofitable, and losses have increased over the past 5 years at a rate of 43.2% per year.

Accelerating Growth: Unable to compare EFTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EFTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: EFTR has a negative Return on Equity (-4187.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies